The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Clinical trial enrollment has long been a bottleneck in drug development
The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
The approval of Augmentin XR, granted to USAntibiotics, directly supports the CNPV program’s goals
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
Subscribe To Our Newsletter & Stay Updated
